Physicians and Healthcare Providers

More information.  More informed prescription and management.

Clozapine is considered by many to be the most effective treatment for refractory schizophrenia on the market today. But the decision to begin treatment with clozapine can be difficult for both physicians and their patients due to the significant risk of agranulocytosis.

Now, PGxPredict™:CLOZAPINE provides important and relevant information about your patients’ risk of clozapine-induced agranulocytosis.

PGxPredict™:CLOZAPINE will enable practitioners to assess a patient's risk of developing clozapine-induced agranulocytosis (CIA). For the first time, it will be possible to:

• Assess whether a patient has a higher or lower risk of developing agranulocytosis - before clozapine is prescribed.
• Make more informed decisions about the frequency of hematological monitoring¹, and about treatment decisions in the face of falling white blood cell counts.

One simple test can provide important information and help you make a more informed decision whether to prescribe or continue clozapine. That's the value of PGxPredict™:CLOZAPINE.

¹This test does not eliminate the need for blood monitoring as recommended in the clozapine prescribing information.